Ono Pharmaceutical Company, Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ono Pharmaceutical Company, Ltd.
Prestige Consumer Stays In Motion In Goody’s Ad Campaign, Gets Moving In Dramamine Sweepstakes
“Get To Good” campaign features “characters who embody the Goody’s consumer, leading active lives and refusing to be slowed down by pain,” while Dramamine’s “Ditch the Drama Sweepstakes” offers “dream vacation anywhere in the world” and introduces “Drama Llama” as “spokescharacter.”
Deal Watch: Gilead Grows Oncology, Inflammation Pipeline With XinThera Buy
The XinThera deal gives Gilead multiple PARP1 and MK2 inhibitors. Also, Roche licenses a HER2 kinase inhibitor from Zion, Amgen partners with TScan in Crohn’s disease and Baxter sells the last of its biopharma operations – a CDMO business – for $4.5bn.
Oncology’s Hold Over The Pharma Pipeline Increases As Growth Slows
The rate of growth of the pharma pipeline slowed last year as oncology and rare diseases tightened their grip on R&D. There are also further signs of China’s rise in importance in the industry.
Record Sales For US, Canada Hydralyte Marketer Remain Under Brand's International Shadow
Hydration Pharmaceuticals Company’s Hydralyte revenues come from limited footprint in rapidly growing sports beverage market while Prestige Consumer Healthcare’s Hydralyte footprint is limited only by not competing with Hydration Pharmaceuticals in US and Canada.
- Generic Drugs
- Other Names / Subsidiaries
- Ono Pharma Korea Co., Ltd., Ono Venture Investment Fund I, L.P., Ono Venture Investment, Inc., Ono Pharma UK Ltd.
- Ono Pharmaceutical Co., Ltd.
- Ono Pharma Taiwan Co., Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.